GEFISOL 250 Tablet: Gefitinib IP 250 mg

Name: GEFISOL 250: Gefitinib IP 250 mg Tablet | High-Value Oncology PCD Pharma Franchise
Brand: Gefisol 250 Tablet
Rating: 4.8 (150 reviews)

Comprehensive Efficacy: Targeting the Driver Mutation in NSCLC

The Gold Standard Combination for Metastatic NSCLC Management

Synergistic Mechanism: EGFR Tyrosine Kinase Inhibition and Tumor Growth Reduction

High Market Demand in the Global Oncology Epidemic

Oncology Monopoly Rights: PCD Franchise Opportunity

Home/Products /gefitinib-ip-250-mg-tablet

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Targeted cancer therapy tablet box for oncology specialists

High-margin, ethical Gefitinib product for PCD Franchise

GEFISOL 250: First-line NSCLC treatment solution

GEFISOL 250 Tablet (Gefitinib IP 250 mg) Product Technical Literature and Usage Guidelines PDF

Gefisol 250 Tablet

Composition : Gefitinib IP 250 mg Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Contact For Business Query

GEFISOL 250 Tablet (Gefitinib IP 250 mg) is a crucial oral oncological medicine, belonging to the class of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). It is specifically indicated as first-line therapy for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors harbor specific EGFR-TK activating mutations (such as exon 19 deletions or L858R substitution).

The drug works by blocking the intracellular phosphorylation required for tumor cell survival and proliferation, thereby interfering with the growth and spread of cancer cells. As a highly selective targeted agent, Gefitinib offers significant improvements in progression-free survival (PFS) and a more favorable tolerability profile compared to traditional chemotherapy in mutation-positive patients.

The market for targeted cancer therapies is growing exponentially, driven by rising NSCLC incidence and mandatory genetic screening. Securing the distribution rights for a specialized, high-cost medicine like GEFISOL 250 positions you at the forefront of the profitable Oncology segment. We offer an exclusive PCD Pharma Franchise opportunity with complete Monopoly Rights in your territory. Partner with us for a high-value product, ethical business practices, assured stock availability, and dedicated promotional support targeting oncologists and specialty hospitals.

About the Product

May cause headache, muscle pain, nausea, abdominal discomfort, or mild liver enzyme elevation. Rarely, serious muscle problems (myopathy or rhabdomyolysis) may occur.

Primary hypercholesterolemia Mixed dyslipidemia Familial hypercholesterolemia Prevention of cardiovascular disease in high-risk patients

Take under medical supervision, preferably once daily, with or without food. Regular liver function and lipid profile monitoring is advised. Inform your doctor about any muscle pain, weakness, or pre-existing liver/kidney conditions. Avoid excessive alcohol intake.

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.